1. Home
  2. AVBP vs BDN Comparison

AVBP vs BDN Comparison

Compare AVBP & BDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVBP
  • BDN
  • Stock Information
  • Founded
  • AVBP 2021
  • BDN 1986
  • Country
  • AVBP United States
  • BDN United States
  • Employees
  • AVBP N/A
  • BDN N/A
  • Industry
  • AVBP
  • BDN Real Estate Investment Trusts
  • Sector
  • AVBP
  • BDN Real Estate
  • Exchange
  • AVBP NYSE
  • BDN Nasdaq
  • Market Cap
  • AVBP 862.8M
  • BDN 731.6M
  • IPO Year
  • AVBP 2024
  • BDN N/A
  • Fundamental
  • Price
  • AVBP $18.66
  • BDN $3.82
  • Analyst Decision
  • AVBP Strong Buy
  • BDN Hold
  • Analyst Count
  • AVBP 8
  • BDN 1
  • Target Price
  • AVBP $38.38
  • BDN $5.00
  • AVG Volume (30 Days)
  • AVBP 239.9K
  • BDN 2.8M
  • Earning Date
  • AVBP 08-13-2025
  • BDN 07-23-2025
  • Dividend Yield
  • AVBP N/A
  • BDN 15.73%
  • EPS Growth
  • AVBP N/A
  • BDN N/A
  • EPS
  • AVBP N/A
  • BDN N/A
  • Revenue
  • AVBP N/A
  • BDN $306,596,000.00
  • Revenue This Year
  • AVBP N/A
  • BDN $59.84
  • Revenue Next Year
  • AVBP N/A
  • BDN $0.13
  • P/E Ratio
  • AVBP N/A
  • BDN N/A
  • Revenue Growth
  • AVBP N/A
  • BDN N/A
  • 52 Week Low
  • AVBP $15.47
  • BDN $3.41
  • 52 Week High
  • AVBP $36.37
  • BDN $6.54
  • Technical
  • Relative Strength Index (RSI)
  • AVBP 29.95
  • BDN 30.61
  • Support Level
  • AVBP $21.10
  • BDN $3.97
  • Resistance Level
  • AVBP $22.29
  • BDN $4.05
  • Average True Range (ATR)
  • AVBP 1.02
  • BDN 0.13
  • MACD
  • AVBP -0.29
  • BDN -0.04
  • Stochastic Oscillator
  • AVBP 2.38
  • BDN 2.59

About AVBP ARRIVENT BIOPHARMA INC

ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.

About BDN Brandywine Realty Trust

Brandywine Realty Trust engaged in the acquisition, development, redevelopment, ownership, management, and operation of a portfolio of office, life science/lab, residential, and mixed-use properties. The company owned and managed properties within five segments. The Philadelphia CBD segment includes properties located in the City of Philadelphia in Pennsylvania. The Pennsylvania Suburbs segment includes properties in Chester, Delaware and Montgomery counties in the Philadelphia suburbs. The Austin, Texas segment includes properties in the City of Austin, Texas. The Metropolitan Washington, D.C. segment includes properties in Northern Virginia, Washington, D.C. and Southern Maryland. The Other segment includes properties in Camden County, New Jersey and New Castle County, Delaware.

Share on Social Networks: